Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Nexien BioPharma Inc (EM) NXEN

Healthcare Biotechnology Drug Manufacturers - Specialty & Generic
Nexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions in the United States. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based... see more

Recent & Breaking News (EXPM:NXEN)

    Nexien BioPharma, Inc. Engages CORE IR for Investor Relations, Public Relations and Shareholder Communications Services

    GlobeNewswire February 19, 2021

    Nexien BioPharma, Inc. Has Been Issued a U.S. Patent for the Methods and Compositions for Treating Non-Dystrophic Myotonia and Myotonic Dystrophies Types 1 and 2

    Business Wire July 16, 2020

    Nexien BioPharma announces that it has been granted a patent by the Israeli Patent Office covering the use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity - two common nerve agents

    Business Wire July 18, 2019

      Podcasts